Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Afc Gamma, Inc. (AFCG)
Property Solutions Acquisition II (PSAGU)
Khosla Ventures Acquisition Co. (KVSA)
Twin Ridge Capital Acquisition (TRCA.U)
Rxr Acquisition (RXRAU)
Interprivate II Acquisition (IPVA.U)
Interprivate III Financial Partners (IPVF.U)
Aurora Acquisition Corp. (AURCU)
ALTIMAR ACQUISITION CORP. III (ATAQU)
Lerer Hippeau Acquisition Corp. (LHAA)
Universe Pharmaceuticals (UPC)
Roblox Corporation (RBLX)
First High-school Education Group Co., Ltd. (FHS)
Coupang, Inc. (CPNG)
Hayward Holdings, Inc. (HAYW)
Priced IPO
Innovage Holding Corp (INNV)
Oscar Health, Inc. (OSCR)
Score Media And Gaming, Inc. (SCR)
Briacell Therapeutics Corp. (BCTX)
Clip Interactive, LLC (AUDD)
Greenbox Pos (GBOX)
Virpax Pharmaceuticals, Inc. (VRPX)
Urban-gro (UGRO)
Neximmune, Inc. (NEXI)
Longeveron (LGVN)
Talis Biomedical Corporation (TLIS)
Decibel Therapeutics, Inc. (DBTX)
Loandepot, Inc. (LDI)
Bumble, Inc. (BMBL)
Apria, Inc. (APR)
Signify Health, Inc.. (SGFY)
Bioventus Inc. (BVS)
Biophytis SA (BPTS)
Vallon Pharmaceuticals (VLON)
Viant Technology Inc. (DSP)
More companies

Evaxion Biotech A/s (EVAX)

Sector - Healthcare

Price chart

-29.7%
Return from IPO

Company News

IPO Profile

About company

They are a clinical-stage AI-immunology platform company using their proprietary artificial intelligence, or AI, technology, engineering expertise and drug development know-how to simulate the human immune system and generate predictive models to identify and develop novel immunotherapies for the treatment of various cancers, bacterial diseases and viral infections. Using the powerful AI technology of their PIONEER and EDEN platforms, they are currently developing four product candidates: EVX-01, for the treatment of metastatic and unresectable melanoma, non-small cell lung cancer, or NSCLC, and bladder cancer; EVX-02, for the adjuvant treatment of melanoma; EVX-03, for multiple cancer indications; and EVX-B1, a vaccine for the prevention of Staphylococcus aureus, or S. aureus (including Methicillin-resistant S. aureus, or MRSA), induced skin and soft tissue infections, or SSTI. Their two lead product candidates, EVX-01 and EVX-02, are both currently in Phase 1/2a trials. Their decision to move into a Phase 2b trial with these product candidates will be made based on the data readout from their ongoing trials. Upon completion of successful Phase 2b, proof-of-concept, or PoC, trials, they plan to monetize their current product candidates via out-licensing arrangements with pharmaceutical partners.
Industry
Biological Products (no Diagnostic Substances)
CEO CFO
Lars Staal Wegner Glenn S. Vraniak
Employees Founded
35 2008

Contacts

Address: Bredgade 34E 1260 Copenhagen K Denmark

Telephone: +45 53 53 18 50

Web page: http://www.evaxion-biotech.com

IPO information

Expected Date 2/5/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 2.75
Shares Revised (MM) 3
Expected offer amount (MM) $30.25
Realized offer amount(MM) $30

Financial Data (last reporting year)

Market Cap (MM) $208.45
Revenues (MM) $0
Net Income (Loss) (MM) $-14.3

Voting

What do you think will happen with the EVAX share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Oppenheimer

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Oppenheimer
CO-Managers
Ladenburg Thalmann

Sector: Healthcare

Tweets about $EVAX

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats